89BIO (ETNB) Expected to Announce Quarterly Earnings on Monday

Key Points

• 89BIO is expected to release its Q2 2025 earnings on August 4th, anticipating earnings of ($0.49) per share.
• The company reported a previous EPS of ($0.49), slightly beating analysts' estimates, and has an average PE ratio of -2.84 with a market cap of $1.40 billion.
• Insider trading activity includes Quoc Le-Nguyen selling 10,461 shares, revealing a 3.27% decrease in ownership, while institutional investors like Goldman Sachs have increased their holdings significantly.

89BIO (NASDAQ:ETNB - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 4th. Analysts expect 89BIO to post earnings of ($0.49) per share for the quarter.

89BIO (NASDAQ:ETNB - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.01. During the same quarter in the previous year, the firm posted ($0.54) earnings per share. On average, analysts expect 89BIO to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

89BIO Trading Down 0.6%

Shares of 89BIO stock traded down $0.06 during mid-day trading on Thursday, hitting $9.47. The stock had a trading volume of 501,311 shares, compared to its average volume of 2,118,871. The firm has a 50-day moving average of $10.03 and a two-hundred day moving average of $8.76. 89BIO has a 12-month low of $4.16 and a 12-month high of $11.84. The company has a quick ratio of 18.03, a current ratio of 18.03 and a debt-to-equity ratio of 0.06. The firm has a market cap of $1.38 billion, a P/E ratio of -2.80 and a beta of 1.28.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ETNB. Weiss Ratings restated a "sell (d-)" rating on shares of 89BIO in a report on Tuesday. Cantor Fitzgerald upgraded shares of 89BIO to a "strong-buy" rating in a report on Wednesday, April 30th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $26.43.

Insider Transactions at 89BIO

In other 89BIO news, insider Quoc Le-Nguyen sold 10,461 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $11.02, for a total transaction of $115,280.22. Following the completion of the sale, the insider directly owned 309,364 shares in the company, valued at $3,409,191.28. The trade was a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On 89BIO

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of 89BIO by 50.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,798 shares of the company's stock valued at $1,954,000 after purchasing an additional 90,107 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of 89BIO by 23.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 995,449 shares of the company's stock valued at $7,237,000 after purchasing an additional 188,367 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of 89BIO by 42.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,856 shares of the company's stock valued at $535,000 after purchasing an additional 21,702 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of 89BIO in the first quarter worth approximately $583,000.

About 89BIO

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.